CANCER TREATMENT DRUGS
Could cancer finally have a targeted cure? Groundbreaking study reveals potential pathway to stop tumor growth without harming healthy cells
A breakthrough in cancer research offers new hope. Scientists have created compounds that halt tumor growth while protecting healthy cells. This experimental therapy is now entering human trials. If successful, it could treat many cancers. The approach targets the RAS gene, crucial in about one in five cancers. This innovation promises a new era in cancer treatment.
Lenskart's pre-IPO capital rush; Capgemini seals WNS deal
Lenskart is expected to close a pre-IPO fundraise ahead of its planned listing. This and more in today's ETtech Top 5.
Cancer cure using AI: Google’s DeepMind AI makes breakthrough in cancer treatment research, turning ‘cold’ tumors ‘hot’
Google DeepMind's artificial intelligence has discovered a new way to fight cancer. The AI model, Cell2Sentence-Scale 27B, identified a drug that can make 'cold' tumors more visible to the immune system. This discovery was confirmed through experiments with living cells. This breakthrough offers a promising new path for developing advanced cancer therapies.
Top US doctor reveals truth about viral weight loss wonder drug Mounjaro. Is it safe or not after potential kidney problem claims?
Beyond common side effects, regular use of Mounjaro may lead to serious health risks, including pancreatitis, kidney problems, and in rare cases, vision issues. Dr. Pal Manickam, an American board-certified gastroenterologist, also issued a strong warning for patients with a history of thyroid cancer or gastrointestinal disorders, advising them to avoid the drug entirely.
Deadly fatty liver could be reversed with this surprising two-drug heart combo, as per doctors
Doctors have found hope for fatty liver disease using two common heart drugs. The new study from the University of Barcelona shows this combo might help reduce liver fat and improve liver health. More tests on humans are needed, but experts say it could be a big step in treating fatty liver safely.
As Nifty & Sensex recover, these large-caps have ‘strong buy’, ‘buy’ recos, with an upside potential of more than 28%
There’s this old saying in the stock market: Even when the bulls are in control, you can never write off the bears. They have and will make an appearance at regular intervals, sometimes in the form of volatile corrections (whatever be the reason, domestic or global). At this point, the bias is toward the bulls. And this bias may become more pronounced over a period of time. One caveat, though: There should not be trouble in the global market because of the China-US tariff tussle. As an investor, it is important to track the fundamental development in sectors and stay with fundamentally good stocks.
- Go To Page 1
With the tariff threat headache over, time to focus on them again? 8 pharma stocks with upside potential of up to 39%
With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among Indian drug companies. The US healthcare system, too, must be relieved, given that India is the biggest supplier of generic drugs to the American market. Any increase in the cost of these medicines would have led to a disruption in the US healthcare system. Now that the tariff threat – which has been troubling Indian companies for the past year – is seemingly a thing of the past, will things get better on the street for Indian pharma companies?
Pharma companies announce direct-to-consumer sales and price cuts in US
Several drug makers are now selling medicines directly to Americans. This move follows President Trump's push to reduce prescription drug prices. Companies like AbbVie, AstraZeneca, and Pfizer are offering discounts. A new government website, TrumpRx.gov, is planned for early 2026. Patients will soon have more options to access affordable medications.
Breast cancer cases on rise; junk food, lack of exercise contributing factors: Doctors
Breast cancer is a growing concern in India, projected to reach two lakh cases annually by 2030. Experts highlight lifestyle factors like lack of exercise, obesity, and westernized diets as key contributors. Genetic predispositions also play a role, necessitating increased genetic testing and early screening for high-risk individuals.
View: How GST 2.0 strengthens India's healthcare response and advance universal health coverage
GST 2.0 marks an important beginning, but affordability alone cannot secure India's healthcare future. To ensure that today's gains translate into lasting impact, cost relief must go hand in hand with a stronger innovation ecosystem. Patients will benefit most when breakthrough medicines and therapies are developed in India, made affordable through efficient regulation, and scaled up through local manufacturing.
China surgeons perform first Pig-to-Human Liver Transplant. Ray of hope for cancer patients?
American surgeons have in recent years transplanted hearts and kidneys from genetically modified pigs into a small number of living patients, they have shied away from liver xenotransplantation, which poses particularly complex challenges.
What is killing Americans? Cigarettes, heart disease, cancer or diabetes - check here
In the United States, the overall probability of dying from a chronic disease fell markedly from 2001 to 2010 but remained nearly flat over the following nine years.
AstraZeneca gets regulator's nod to market cancer drug in India
AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2-positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour-agnostic indication. This broadens its potential to help more patients with advanced HER2-positive cancers.
As Nifty & Sensex recover, these large-caps have ‘strong buy’, ‘buy’ recos, with an upside potential of more than 26%
We are in a market where, as an investor, either be very agile or be extremely passive. And if you are passive, stick to ETFs. But being agile comes with its own risks (and rewards, of course). As the market continues to move upward, we are probably going to see a phase where the momentum itself becomes fuel for fresh money to flow in. Today, we take a look at stocks that are not only large-cap stocks but are large businesses and strong brands – or have something else that makes them stand out. The focus is also on managing the relationship between upside potential and drawdowns.
Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of key drugs like Mounjaro. This strategic move leverages India's skilled workforce and includes a new Hyderabad facility to oversee contract manufacturing, despite global shifts towards US production.
Just the booster pill Indian pharma needs
Indian Pharma must look at strengthening its presence in established markets in Latin America, China, Russia, Africa and East Europe. This is a timely pill for industry to take.
Jazz Pharma, Roche's combination therapy for lung cancer gets US approval
The FDA has approved Jazz Pharmaceuticals' Zepzelca and Roche's Tecentriq combination as the first and only first-line maintenance treatment for extensive-stage small cell lung cancer. This approval, based on trial data showing reduced disease progression and death risk, offers a new option for this aggressive cancer, making the therapy eligible for reimbursement.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.
TrumpRx website 2025: direct-to-consumer prescription drug platform and Pfizer discount deal explained
President Donald Trump announced TrumpRx, a government-operated website launching early 2026 for discounted prescription drugs. Pfizer agreed to offer medications at 50-85% discounts through direct-to-consumer sales. The site redirects consumers to manufacturers' purchasing channels, not selling drugs directly
Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump
Pfizer agreed to lower drug costs and invest $70 billion in U.S. manufacturing following a deal with the Trump administration. The drugmaker will implement "most-favored-nation" pricing for Medicaid and new drugs, matching international low prices. This move supports Trump's long-standing effort to reduce drug expenses and boost domestic production.
Sameer Wankhede takes Aryan Khan’s series The Bads of Bollywood to court over defamation, seeks damages of Rs 2 crore
Sameer Wankhede has filed a lawsuit in Delhi High Court. He has sued Netflix and Red Chillies Entertainment. The suit concerns the web series Ba**ds of Bollywood. Wankhede alleges defamation and misrepresentation of the 2021 drugs-on-cruise case. He seeks a ban on the series and Rs 2 crore in damages. The money is intended for the Tata Memorial Cancer Hospital.
Former NCB officer Sameer Wankhede moves Delhi HC against Netflix, Red Chillies, claims 'Ba***ds of Bollywood' is defamatory
Sameer Wankhede, the former NCB director, has initiated a defamation suit in the Delhi High Court against Red Chillies Entertainment, Netflix, and others. He claims the series "Ba***ds of Bollywood" contains defamatory content designed to harm his reputation. Wankhede is seeking legal recourse against the show's producers and distributors, asserting that it damages both his professional and personal life.
Study reveals how an accessible medicine could help prevent colorectal cancer relapse
Low-dose aspirin may help prevent colorectal cancer relapse in patients with certain genetic mutations. A new study found daily aspirin can reduce cancer coming back by up to 55%. Researchers say it works by reducing inflammation, stopping tumor growth, and targeting cancer cells. This cheap and widely available drug could save many lives if used carefully.
Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab Rezetecan
Glenmark Pharmaceuticals has partnered with Hengrui Pharma, securing exclusive rights to develop and commercialize Trastuzumab Rezetecan globally, excluding specific major markets. This agreement involves an upfront payment of $18 million to Hengrui, with potential milestone payments reaching $1.093 billion. The collaboration aims to expand the availability of this innovative cancer therapy to more patients worldwide, aligning with Glenmark's oncology strategy.
India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threat
Donald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatments are most vulnerable. India, the world's pharmacy, faces potential export losses. Analysts foresee price hikes and supply chain disruptions. Indian firms may struggle to absorb tariffs. The US aims to boost domestic drug production. This move risks higher drug prices for Americans.
Why is leucovorin being considered as an autism treatment?
The US FDA approved GlaxoSmithKline's leucovorin. This decision followed a review of leucovorin's use in patients. These patients had cerebral folate deficiency. This deficiency can cause neurological symptoms. Some of these symptoms are also seen in autism. Studies suggest a link between folate processing and autism. However, experts emphasize the need for more research.
Trump says the new wonder drug leucovorin is the answer to Autism treatment - here's how it will help children with ASD
The Trump administration has highlighted leucovorin, a drug usually used in cancer treatment, as a possible therapy for autism, with previous trials citing it may enhance interaction in children with ASD. President Trump explained it as “amazing” and an “answer to autism.”
When will Trump announce Tylenol-autism link? Can leucovorin decrease its symptoms?
Donald Trump is expected to announce a possible link between Tylenol and autism. The announcement is scheduled after a press briefing by Karoline Leavitt. Federal health officials are expected to warn pregnant women against using Tylenol unless they have a fever. They may also suggest leucovorin as a possible treatment for autism. Robert F. Kennedy Jr.
Alkem launches breast cancer biosimilar in India
Alkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously developed and manufactured injection of 420mg/14mL aims to provide an affordable treatment option. Alkem's CEO, Vikas Gupta, highlighted the launch as a commitment to strengthening their oncology portfolio and expanding access to crucial treatments.
Load More
